癌症诊断强调了对灵敏和精确工具的迫切需求，生物标志物在促进早期检测和肿瘤诊断方面发挥着关键作用。尽管睾丸肿瘤具有经典的病理学分类，但缺乏有价值的标志物，这强调了在临床管理中识别和应用血清肿瘤标志物的必要性。不幸的是，现有的生物标志物表现出有限的敏感性和特异性。近年来，新型 RNA 分子的发现，为诊断工具和有前途的生物标志物带来了潜在的突破。该报告提供了令人信服的证据，支持通过应用一组九种 microRNA (miRNA) 来检测早期睾丸癌，将它们确立为有价值的诊断血清生物标志物。我们开发了标准化的基于血清的测量方案，并对数据集进行了全面的统计分析，以强调 miRNA 池的诊断准确性。值得注意的是，在睾丸癌中，miR-21、miR-29a 和 miR-106b 的敏感性超过了经典的血清肿瘤标志物，其敏感性超过 93%。具体来说，这些 miRNA 有望增强睾丸癌检测中的临床决策，并具有在监测化疗结果中评估肿瘤生长的潜力。© 2024。作者。

The imperative need for sensitive and precise tools is underscored in cancer diagnostics, with biomarkers playing a pivotal role in facilitating early detection and tumor diagnosis. Despite their classical pathological classification, testicular tumors lack valuable markers, emphasizing the necessity to identify and apply serum tumor markers in clinical management. Unfortunately, existing biomarkers exhibit limited sensitivities and specificities. Recent years have witnessed the discovery of novel RNA molecules, presenting a potential breakthrough as diagnostic tools and promising biomarkers. This report presents compelling evidence supporting the detection of early testicular cancer by applying a set of nine microRNAs (miRNAs), establishing them as valuable serum biomarkers for diagnosis. We developed a standardized serum-based measurement protocol and conducted comprehensive statistical analyses on the dataset to underscore the diagnostic accuracy of the miRNA pool. Notably, with a sensitivity exceeding 93%, miR-21, miR-29a, and miR-106b surpass classical serum tumor markers in the context of testicular cancer. Specifically, these miRNAs are poised to enhance clinical decision-making in testicular cancer detection and hold the potential for assessing tumor growth in monitoring chemotherapy outcomes.© 2024. The Author(s).